Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Hartung HP, Polman C, Bertolotto A, Deisenhammer F, Giovannoni G, Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. Hartung HP, et al. Among authors: bertolotto a. J Neurol. 2007 Jul;254(7):827-37. doi: 10.1007/s00415-006-0486-3. Epub 2007 Apr 24. J Neurol. 2007. PMID: 17457510 Review.
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung HP, Hemmer B, Killestein J, McFarland HF, Oger J, Pachner AR, Petkau J, Reder AT, Reingold SC, Schellekens H, Sørensen PS. Polman CH, et al. Among authors: bertolotto a. Lancet Neurol. 2010 Jul;9(7):740-50. doi: 10.1016/S1474-4422(10)70103-4. Lancet Neurol. 2010. PMID: 20610349
Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F. Hegen H, et al. Among authors: bertolotto a. Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5. Mult Scler. 2014. PMID: 24009164
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis.
Farrell R, Bendtzen K, Bertolotto A, Clark B, Comabella M, Deisenhammer F, Fogdell-Hahn A, Giovannoni G, Hartung HP, Hemmer B, Hillert J, Kappos L, Killestein J, Lindberg R, Montalban X, Polman C, Sorensen PS; European NABINMS Consortium. Farrell R, et al. Among authors: bertolotto a. J Int Med Res. 2008 Jan-Feb;36(1):204-8; author reply 208-10. J Int Med Res. 2008. PMID: 18230281 No abstract available.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Hegen H, Adrianto I, Lessard CJ, Millonig A, Bertolotto A, Comabella M, Giovannoni G, Guger M, Hoelzl M, Khalil M, Fazekas F, Killestein J, Lindberg RL, Malucchi S, Mehling M, Montalban X, Rudzki D, Schautzer F, Sellebjerg F, Sorensen PS, Deisenhammer F, Steinman L, Axtell RC. Hegen H, et al. Among authors: bertolotto a. Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(2):e202. doi: 10.1212/NXI.0000000000000202. eCollection 2016 Apr. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 26894205 Free PMC article.
Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.
Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, Hintzen R, Jeromin A, Havrdova E, Tumani H, Bertolotto A, Comabella M, Frederiksen J, Álvarez-Cermeño JC, Villar L, Galimberti D, Myhr KM, Dujmovic I, Fazekas F, Ionete C, Menge T, Kuhle J, Keir G, Deisenhammer F, Teunissen C, Giovannoni G. Gnanapavan S, et al. Among authors: bertolotto a. Neurology. 2014 Sep 23;83(13):1210-6. doi: 10.1212/WNL.0000000000000809. Epub 2014 Aug 22. Neurology. 2014. PMID: 25150289
372 results